---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-094533"
form_type: "8-K"
ticker: "IPSC"
cik: "0001850119"
company_name: "Century Therapeutics, Inc."
filed_at: "2026-08-12T12:12:12+00:00"
generated_at: "2026-08-12T12:15:09.163075+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Century Therapeutics Q2 2026: Net loss $34.6M, cash $197.2M, CNTY-813 IND on track for 4Q26

## Summary
- Q2 2026 net loss $34.6M vs $32.5M in Q2 2025; R&D $19.6M (down from $26.9M), G&A $5.8M (down from $7.8M).
- Cash, equivalents and investments $197.2M at June 30, 2026, up from $117.1M at Dec 31, 2025; runway into 1Q 2029.
- FDA pre-IND alignment for CNTY-813; IND submission on track for 4Q 2026, initial data expected 2H 2027.
- CNTY-308, CD19-targeted CAR-iT therapy with Allo-Evasion 5.0, remains on track to enter clinic in 2026.
- Preclinical data at ADA 2026 showed durable glucose control >8 months; oral presentations at EASD and CRC 2026.

## SEC filing metadata
- accession: 0001104659-26-094533
- form_type: 8-K
- ticker: IPSC
- cik: 0001850119
- company_name: Century Therapeutics, Inc.
- filed_at: 2026-08-12T12:12:12+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1850119/000110465926094533/0001104659-26-094533-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1850119/000110465926094533/tm2622911d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-094533
- JSON: https://secwatch.observer/filing/0001104659-26-094533.json
- Plain text: https://secwatch.observer/filing/0001104659-26-094533.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.